Acacia Pharma Limited

Darwin Discovery Limited

Sosei R&d Ltd.

Medeva Europe Limited

Arakis Ltd.

Julian Clive Gilbert

Robert William Gristwood

Gabriel Fox

Nicola Cooper

Andrew John McGlashan Richards

Robin Mark Bannister

John Nicholas Staniforth

Hazel Judith Bardsley

David A V Morton

Michael Grant Wyllie

Andrew John Richards

Helen Frances Baker

David A Morton

John Staniforth

Amisulpride is useful in the treatment of postoperative nausea and/or vomiting in a patient, wherein the patient has already been administered a prophylaxis drug for postoperative nausea and/or vomiting, and wherein the dose of amisulpride is 7.5 to 15 mg.

Rescue treatment of post operative nausea and vomiting

Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.

Use of amisulpride as an anti-emetic

A kit comprises at least one non-IV injectable unit dose of amisulpride and at least one dose of an acute-phase anti-emetic, for simultaneous, separate or sequential use in the treatment or prevention of chemotherapy- or radiotherapy-induced nausea and/or vomiting in a subject, wherein the subject is receiving or has received a chemotherapy or radiotherapy treatment regimen, and wherein the dosage regimen comprises the administration of the or each acute-phase anti-emetic on day 1, day 1 being the same day that a chemotherapy or radiotherapy is administered, and the administration of the, or at least one of the, non-IV injectable unit doses of amisulpride on day 2. Also provided is a kit comprising at least one non-IV injectable unit dose of amisulpride and at least one unit dose of IV amisulpride. Further provided is a non-IV injectable formulation of amisulpride, for use in the treatment or prevention of delayed-phase chemotherapy- or radiotherapy-induced nausea and/or vomiting in a subject.

Combinations of amisulpride and another anti-emetic for treating nausea and vomiting

Bethanechol is administered topically, for the treatment of xerostomia.

Use of bethanechol for treatment of xerostomia

The present invention is a product comprising a &#x3b2;2 agonist and a progestin, as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of muscle loss. The present invention is also a &#x3b2;2 agonist selected from R,R-formoterol, indacaterol or ritodrine, for use in the treatment or prevention of muscle loss.

Drug combination and its use in the treatment of muscle loss

Growing community of inventors

Cambridgeshire, United Kingdom

Julian Clive Gilbert